Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • 16 years old team of young researchers developed salt-powered mini fridge for vaccine transport and storage
    22 April 2025

    16 years old team of young researchers developed salt-powered mini fridge for vaccine transport and storage

    Team of Young researchers, still in Indian school, developed a portable, electricity-free refrigeration unit using a salt solution to keep vaccines and other temperature-sensitive materials cool. Team consisting of Dhruv Chaudhary, Mithran Ladhania, and Mridul Jain, is known for their work on Thermavault, a device designed to transport vaccines, medicines, and even transplant organs.

  • 22 April 2025
    Novo Nordisk to stop selling its top insulin brand from India
    Novo Nordisk to stop selling its top brand Human Mixtard from India which is country's top selling insulin alone Rs. 800 Crore. Human Mixtard comes under DPCO and the company is reported to come up with new products in India.
  • 21 April 2025
    Key Enzyme in Lipid Metabolism Linked to Immune System Aging

    Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren’t completely sure why. They may have a better idea now, however, thanks to a new study in GeroScience.

  • 21 April 2025
    Integrative approach reveals promising candidates for AD risk factors or targets for treatments

    A study published in the American Journal of Human Genetics by researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital provides solutions to the pressing need to identify factors that influence Alzheimer’s disease (AD) risk or resistance while providing an avenue to explore potential biological markers and therapeutic targets.

  • 18 April 2025
    Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur
    Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
  • 17 April 2025
    Microorganisms employ a secret weapon during metabolism
    In the global carbon cycle microorganisms have evolved a variety of methods for fixing carbon. Researchers from Bremen and Taiwan have investigated the methods that are utilized at extremely hot, acidic and sulfur-rich hydrothermal vents in shallow waters off the island of Kueishantao, Taiwan.
  • 17 April 2025
    Common genetic variants linked to drug-resistant epilepsy
    Antiseizure medication is usually prescribed for people with the condition. However, for one in three people with epilepsy around 20 million individuals worldwide, current antiseizure medications are ineffective. This means that people will continue to have seizures despite taking medication – a condition called ‘drug resistance.
  • 14 April 2025
    Stevens Researchers Put Glycemic Response Modeling On a Data Diet
    In a paper in the Journal of Diabetes Science and Technology, researchers at Stevens Institute of Technology offer a new approach: a data-sparse model capable of accurately predicting individual glycemic responses with no need for blood draws, stool samples, or other unpleasant testing. The key to their approach? Keeping track of what people actually eat.
  • 14 April 2025
    FDA clears IND for clinical trial testing switchable CAR-T therapy in patients with autoimmune diseases, without chemotherapy
    Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with autoimmune conditions. Patient recruitment for the phase 1 trial will begin soon.
  • 14 April 2025
    Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
    Sandoz the global leader in generic and biosimilar medicines announced the filing of an antitrust lawsuit in the US against Amgen, Inc. , for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel etanercept, first approved by the US Food and Drug Administration in 1998.
Subscribe to Pharma News